MedTrace Logo

Treatment of Patients With Advanced Rectum Cancer With Capecitabine and Oxaliplatin Before, Under and After Radiation and With Adding Cetuximab to K-RAS Wild-type Patients

NCT00964457 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2009-08-25

No results posted yet for this study

Summary

response rate to adding cetuximab, oxaliplatin and capecitabine to radiation for advanced rectum cancer

Conditions

  • Rectum Cancer

Interventions

DRUG

cetuximab

cetuximab 500mg per meter square every second week

Sponsors & Collaborators

  • Copenhagen University Hospital at Herlev

    lead OTHER

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-08-31
Primary Completion
2012-07-31
Completion
2017-07-31

Countries

  • Denmark

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00964457 on ClinicalTrials.gov